Get notified when SLDB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Shares of Our Common Stock Having an Aggregate Offering Price of Up to $85,000,000. (new) — The at-the-market offering could increase the share count by up to 43%, causing substantial dilution to existing shareholders.
- In October 2020, In Connection With the Execution of Our Collaboration and License Agreement With Ultragenyx Pharmaceuticals, Inc., or Ultragenyx, We Issued and Sold 521,719 Shares of Our Common Stock to Ultragenyx. (new) — Prior private placements to named counterparties create share overhang that may depress the stock price.
Solid Biosciences launches at-the-market offering of up to $85M at $2.55/share, implying $282.6M market cap
Filed May 15, 2025 · ~1 min read
Key Changes
-
high
Solid Biosciences is offering up to $85 million of common stock in an at-the-market program, with shares sold at prevailing market prices over time.
The Offering verify on EDGAR → -
high
The assumed offering price is $2.55 per share, the last sale price on May 14, 2025; actual prices will vary with market conditions.
The Offering verify on EDGAR → -
high
After the offering, up to 110.8 million shares will be outstanding, a 43% increase from 77.5 million shares as of March 31, 2025, causing substantial dilution.
The Offering verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NTSK 10-Q) is open in full — no account needed.
Partner
Trade SLDB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify